Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joycelyn Sim

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
European Journal of Haematology|August 20, 2014
LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimensChor Sang Chim, Joycelyn Sim, Sidney Tam, et al.
Annals of Hematology|April 2, 2011
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemiaEric Tse, Anskar Y H Leung, Joycelyn Sim, et al.
Clinical Kidney Journal|June 1, 2023
Clinico-pathological correlations and outcomes of <i>de novo</i> glomerular diseases in patients after haematopoietic stem cell transplantationDesmond Y H Yap, Davina Lie, Tiffany Lau, et al.
Annals of Hematology|June 17, 2023
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reactionVivian W K Li, Rita Yim, Paul Lee, et al.
Transfusion|March 29, 2019
Transfusion of pathogen-reduced platelet components without leukoreductionJoycelyn Sim, Wai Chiu Tsoi, Cheuk Kwong Lee, et al.
Annals of Hematology|August 17, 2013
Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patientsThomas S Y Chan, Harinder Gill, Yu-Yan Hwang, et al.
Bone Marrow Transplantation|February 21, 2024
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MMHoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang, et al.
Journal of Hematology & Oncology|June 12, 2012
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTDChor Sang Chim, Albert Kwok Wai Lie, Eric Yuk Tat Chan, et al.
Blood Cell Therapy|January 30, 2023
The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific regionMinako Iida, Anthony Dodds, Mafruha Akter, et al.
Therapeutic Advances in Hematology|April 25, 2022
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gainHoi Ki Karen Tang, Chi Yeung Fung, Gareth J Morgan, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
European Journal of Haematology|August 20, 2014
LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimensChor Sang Chim, Joycelyn Sim, Sidney Tam, et al.
Annals of Hematology|April 2, 2011
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemiaEric Tse, Anskar Y H Leung, Joycelyn Sim, et al.
Clinical Kidney Journal|June 1, 2023
Clinico-pathological correlations and outcomes of <i>de novo</i> glomerular diseases in patients after haematopoietic stem cell transplantationDesmond Y H Yap, Davina Lie, Tiffany Lau, et al.
Annals of Hematology|June 17, 2023
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reactionVivian W K Li, Rita Yim, Paul Lee, et al.
Transfusion|March 29, 2019
Transfusion of pathogen-reduced platelet components without leukoreductionJoycelyn Sim, Wai Chiu Tsoi, Cheuk Kwong Lee, et al.
Annals of Hematology|August 17, 2013
Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patientsThomas S Y Chan, Harinder Gill, Yu-Yan Hwang, et al.
Bone Marrow Transplantation|February 21, 2024
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MMHoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang, et al.
Journal of Hematology & Oncology|June 12, 2012
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTDChor Sang Chim, Albert Kwok Wai Lie, Eric Yuk Tat Chan, et al.
Blood Cell Therapy|January 30, 2023
The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific regionMinako Iida, Anthony Dodds, Mafruha Akter, et al.
Therapeutic Advances in Hematology|April 25, 2022
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gainHoi Ki Karen Tang, Chi Yeung Fung, Gareth J Morgan, et al.
Pageof 2